文献速递乳腺癌头颈与中枢神经肿瘤

PI3K-AKT-mTOR通路单核苷酸多态性与转移性乳腺癌中枢神经系统转移风险

Identification of single nucleotide polymorphisms of the PI3K-AKT-mTOR pathway as a risk factor of central nervous system metastasis in metastatic breast cancer.
PubMed 文献 · Eur J Cancer · 2017-11-02

多因素分析显示AKT1-rs3803304、AKT2-rs3730050、PDK1-rs11686903与PI3KR1-rs706716与CNS转移相关;PI3KR1-rs706716或可纳入预测复合评分以早期识别CNS转移。

要点

  • PI3KR1-rs706716经Bonferroni校正后单因素分析与CNS转移相关(p<0.00085)。
  • 多因素分析显示AKT1-rs3803304、AKT2-rs3730050、PDK1-rs11686903与PI3KR1-rs706716与CNS转移相关。
  • 激素受体状态、HER2状态及血管瘤栓与CNS转移风险相关。

核心结论

  • PI3KR1-rs706716可能与转移性乳腺癌患者CNS转移相关,或可纳入预测复合评分以早期检出CNS转移,且不受乳腺癌亚型限制。

研究设计与样本

  • GENEOM研究(NCT00959556)收集接受新辅助、辅助或转移阶段治疗的乳腺癌患者血样。
  • 无CNS转移定义为无神经系统症状或死亡前/5年随访期间脑MRI正常。

主要发现

  • 单因素分析经Bonferroni校正后,仅PI3KR1-rs706716与CNS转移相关(p<0.00085)。
  • 多因素分析显示AKT1-rs3803304、AKT2-rs3730050、PDK1-rs11686903与PI3KR1-rs706716与CNS转移相关。
  • 临床参数中激素状态、HER2状态及血管瘤栓与CNS转移风险相关。

关键数值与推荐

  • Bonferroni校正后单因素显著阈值p<0.00085,仅PI3KR1-rs706716达到该阈值。
  • CNS转移判定标准:出现CNS转移,或对照为无神经系统症状或死亡前/5年随访期间脑MRI正常。

临床怎么用

  • 对转移性乳腺癌患者可关注PI3KR1-rs706716等SNP,作为CNS转移风险分层与早期监测的候选分子标志。
  • 上述SNP或可纳入预测复合评分,用于不依赖乳腺癌亚型的CNS转移早期检出。
  • 激素状态、HER2状态及血管瘤栓等临床因素也应纳入CNS转移风险评估。

局限性

  • 摘要未报告研究的局限性与验证队列信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The PI3K-AKT-mTOR pathway may be involved in the development of central nervous system (CNS) metastasis from breast cancer. Accordingly, herein we explored whether single nucleotide polymorphisms (SNPs) of this pathway are associated with altered risk of CNS metastasis formation in metastatic breast cancer patients. METHODS: The GENEOM study (NCT00959556) included blood sample collection from breast cancer patients treated in the neoadjuvant, adjuvant or metastatic setting. We identified patients with CNS metastases for comparison with patients without CNS metastasis, defined as either absence of neurological symptoms or normal brain magnetic resonance imaging (MRI) before death or during 5-year follow-up. Eighty-eight SNPs of phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian (or mechanistic) target of rapamycin (mTOR) pathway genes were selected for analysis: AKT1 (17 SNPs), AKT2 (4), FGFR1 (2), mTOR (7), PDK1 (4), PI3KR1 (11), PI3KCA (20), PTEN (17), RPS6KB1 (6). RESULTS: Of 342 patients with metastases, 207 fulfilled the inclusion criteria: One-hundred-and-seven patients remained free of CNS metastases at last follow-up or date of death whereas 100 patients developed CNS metastases. Among clinical parameters, hormonal and human epidermal growth factor receptor-2 (HER2) status as well as vascular tumour emboli was associated with risk of CNS metastasis. Only PI3KR1-rs706716 was associated with CNS metastasis in univariate analysis after Bonferroni correction (p < 0.00085). Multivariate analysis showed associations between AKT1-rs3803304, AKT2-rs3730050, PDK1-rs11686903 and PI3KR1-rs706716 and CNS metastasis . CONCLUSION: PI3KR1-rs706716 may be associated with CNS metastasis in metastatic breast cancer patients and could be included in a predictive composite score to detect early CNS metastasis irrespective of breast cancer subtype.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Le Rhun E, Bertrand N, Dumont A, et al. Identification of single nucleotide polymorphisms of the PI3K-AKT-mTOR pathway as a risk factor of central nervous system metastasis in metastatic breast cancer. Eur J Cancer. 2017. PMID: 29103666. doi:10.1016/j.ejca.2017.10.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。